Repositioning of Antibiotics in the Treatment of Viral Infections
Current Microbiology · 2024-12 · 81 (12)
DOI: 10.1007/s00284-024-03948-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Microbiology, online erschienen am 26.10.2024. Verfasst von Anaíd Bustos-Hamdan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico. Hauptthemen laut MEDLINE: Drug Repositioning, Antiviral Agents, Anti-Bacterial Agents, Virus Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Autónoma Metropolitana, Universidad Autonoma Metropolitana.
Abstract (Originalsprache)
Drug repurposing, also known as drug repositioning, is a currently tested approach by which new uses are being assigned for already tested drugs. In this case there are antibiotics that are used to combat bacterial infections. However, antibiotics are among the drugs that have been studied for possible antiviral activities. Therefore, the aim of this work is to carry out a review of the studies of antibiotics that could be repositioned for the treatment of viral infections. Among the main antibiotics that have demonstrated antiviral activity are macrolides and glycopeptides. In addition, several antibiotics from the group of tetracyclines, fluoroquinolones, cephalosporins and aminoglycosides have also been studied for their antiviral activity. These antibiotics have demonstrated antiviral activity against both RNA and DNA viruses, including the recent pandemic virus SARS-CoV-2. Some of these antibiotics were selected in addition to its antiviral activity for their immunomodulatory and anti-inflammatory properties. Of the antibiotics that present antiviral activity, in many cases the mechanisms of action are not exactly known. The use of these antibiotics to combat viral infections remains controversial and is not generally accepted, since clinical trials are required to prove its effectiveness. Therefore, there is currently no antibiotic approved as antiviral therapy. Hence is necessary to present the studies carried out on antibiotics that can be repositioned in the future as antiviral drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.
- Maestria en Biología de la Reproducción Animal, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City, Mexico.
- Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico. jbustos@correo.xoc.uam.mx.
Förderung
- Universidad Autónoma Metropolitana
- Universidad Autonoma Metropolitana
Zitieren
APA
Bustos-Hamdan, A., Bracho-Gallardo, J. I., Hamdan-Partida, A., & Bustos-Martínez, J. (2024). Repositioning of Antibiotics in the Treatment of Viral Infections. Current Microbiology, 81(12). https://doi.org/10.1007/s00284-024-03948-7
Vancouver
Bustos-Hamdan A, Bracho-Gallardo JI, Hamdan-Partida A, Bustos-Martínez J. Repositioning of Antibiotics in the Treatment of Viral Infections. Current Microbiology. 2024;81(12). doi:10.1007/s00284-024-03948-7
BibTeX
@article{BustosHamdan2024,
author = {Bustos-Hamdan, Anaíd and Bracho-Gallardo, Jair Isidoro and Hamdan-Partida, Aída and Bustos-Martínez, Jaime},
title = {Repositioning of Antibiotics in the Treatment of Viral Infections},
journal = {Current Microbiology},
year = {2024},
volume = {81},
number = {12},
doi = {10.1007/s00284-024-03948-7}
}
EUVIMED